Halozyme (HALO) legal chief receives shares as RSUs vest

Rhea-AI Filing Summary

Halozyme Therapeutics SVP and Chief Legal Officer Mark Howard Snyder reported multiple equity compensation events. On February 20 and 23, 2026, restricted stock units vested and were settled into 5,332 and 7,011 shares of common stock, respectively, through derivative exercises at $0.00 per share.

To satisfy tax withholding obligations, the issuer withheld 2,876 shares at $70.98 and 3,782 shares at $70.64, recorded as tax-withholding dispositions rather than open-market sales. After these transactions, Snyder directly owned 47,610 shares of Halozyme common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Snyder Mark Howard

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF LEGAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		M		5,332	A	$0	47,257	D
Common Stock	02/20/2026		F		2,876(1)	D	$70.98	44,381	D
Common Stock	02/23/2026		M		7,011	A	$0	51,392	D
Common Stock	02/23/2026		F		3,782(2)	D	$70.64	47,610	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	02/20/2026		M			5,332	(3)	(3)	Common Stock	5,332	$0	15,995	D
Restricted Stock Units	$0	02/23/2026		M			7,011	(3)	(3)	Common Stock	7,011	$0	14,022	D

Explanation of Responses:

1. The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

2. The reported disposition of 3,782 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

3. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Halozyme (HALO) insider Mark Howard Snyder report on this Form 4?

Mark Howard Snyder reported vesting and settlement of restricted stock units into Halozyme common stock, along with share dispositions for tax withholding. These transactions reflect routine equity compensation events rather than open-market purchases or sales, and are held under his direct ownership.

How many Halozyme shares did Snyder acquire through RSU vesting?

Snyder acquired 5,332 shares of Halozyme common stock on February 20, 2026, and 7,011 shares on February 23, 2026. Both acquisitions came from the vesting and settlement of restricted stock units, executed at a transaction price of $0.00 per share.

Were any of Snyder’s Halozyme share dispositions open-market sales?

The reported dispositions were not open-market sales. A total of 2,876 shares at $70.98 and 3,782 shares at $70.64 were withheld by Halozyme to cover Snyder’s tax withholding obligations related to RSU vesting, according to the filing’s footnotes.

What is Mark Howard Snyder’s role at Halozyme (HALO)?

Mark Howard Snyder serves as Senior Vice President and Chief Legal Officer at Halozyme Therapeutics. His Form 4 filing reflects equity awards and related tax withholding tied to this executive role, rather than discretionary trading activity in Halozyme’s common stock.

How many Halozyme shares did Snyder own after these transactions?

Following the reported transactions, Snyder directly owned 47,610 shares of Halozyme common stock. This figure reflects his holdings after both the RSU conversions into common shares and the share withholdings used to satisfy tax obligations on February 20 and 23, 2026.

What do the M and F transaction codes mean in Snyder’s Halozyme Form 4?

Code M indicates exercise or conversion of derivative securities, here restricted stock units vesting into common stock. Code F indicates disposition of shares to pay exercise price or tax liabilities, which in this case were shares withheld by Halozyme to satisfy Snyder’s tax withholding obligations.